Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference.
Details are as follows:
Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102
A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. The replay of the presentation will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during this event.
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
13 minutes ago
- Yahoo
Former head trader of Denver-based investing company pleads guilty to insider trading
DENVER (KDVR) — A Connecticut man pleaded guilty to an insider trading charge on Friday for actions he took while employed at Denver-based firm Irving Investors. Ryan Squillante, 40, of Weston, Connecticut, was employed as the head of equity trading at Irving Investors at the time of the offense, according to the U.S. Attorney's Office for the District of Connecticut. While there, he received 'material non-public information' about some publicly traded companies. Australian hacker sentenced in May arrested by HSI Denver, faces deportation Prosecutors say that Squillante used MNPI on 15 different occasions between August 2022 and May 2023 for his own benefit, profiting about $220,912 from the transactions, according to the attorney's office. The U.S. Attorney's Office for the District of Connecticut provided an example of one of the times Squillante reportedly received MNPI about a clinical-stage biopharmaceutical company called Praxis Precision Medicines. Praxis is traded on the NASDAQ. The prosecutors said that between Feb. 27, 2023, and March 2, 2023, Squillante 'sold short' over 38,000 shares of Praxis for an average price per share of $3.04. On March 3, prosecutors say Squillante announced poor results of the company's drug trial before the market opened. Following that announcement, Squillante 'covered' the same number of shares at an average price of $1.82 per share, making a profit of about $46,421. Squillante pleaded guilty to securities fraud, which has a maximum term of imprisonment of 20 years. He's scheduled to be sentenced on Aug. 29. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
13 minutes ago
- Yahoo
30,000 attend ‘Little Poland Festival' in New Britain
NEW BRITAIN, Conn. (WTNH) — Polish music and food filled the streets of New Britain as the community gathered to celebrate the twelfth annual 'Little Poland Festival' Sunday afternoon. The all-day-event was hosted by the Polonia Business Association, a local non-profit that aims to promote New Britain's Polish neighborhood. 'Little Poland continues to grow and the strong business community is a crucial piece of that expansion,' Mayor of New Britain Erin Stewart said. 'There are over 100 businesses in Little Poland that continue to be successful in part due to the close-knit community that works tirelessly to build connections both here and abroad.' Runners take to Standish Park for Wethersfield Community Run The festival is one of the largest cultural celebrations in New England, attracting the company of over 30,000 people with 120 vendor booths, live entertainment and activities. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
